Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01902303 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Cold Sore Treatments on Ultra Violet (UV) Induced Cold Sores
A Phase 2 study of Oral Herpes Simplex, sponsored by Beech Tree Labs.
- Completed
- Registry status
- Phase 2
- Development phase
- 303
- Enrollment target
- 3
- Study locations
NCT01902303: Completed Phase 2 study of Oral Herpes Simplex, sponsored by Beech Tree Labs.
NCT01902303 is a Phase 2 study of Oral Herpes Simplex that has completed, run by Beech Tree Labs. The registered enrollment target is 303 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (128% higher). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01902303, a Phase 2 study of Oral Herpes Simplex, has completed, sponsored by Beech Tree Labs.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 303 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to determine if a new drug treatment is effective to block the development of a cold sore lesion following Ultra Violet (UV) exposure.
Primary Outcome
The primary efficacy endpoint of this study is to determine if a recurrent oral herpes episode initiated with prodromal symptoms is aborted before progressing to a lesion (vesicle stage) via assessing lesion stages by the trained evaluator. Any episode of oral herpes that did not reach a vesicle stage or higher by Day 7 (based on evaluator and self-assessments of legion stage) was considered "aborted" or "blocked". Any episode of oral herpes that reached a vesicle stage or higher by Day 7 was co
Conditions Studied
Interventions
- DRUG Matching Placebo
- DRUG BTL-TML-HSV
Study Locations (3)
Florida
- Hill Top Research - St. Petersburg
Ohio
- Hill Top Research - Cincinnati
South Carolina
- Coastal Carolina Research Center - Mt. Pleasant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 303 participants |
| Start Date | 2013-07 |
| Est. Completion | 2015-02 |
| Phase | Phase 2 |
What the finished NCT01902303 record still lists
NCT01902303 is an interventional study that assigns participants to a tested intervention. The registered 303 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (128% higher).
The record links to 1 condition, with Oral Herpes Simplex appearing as the primary indexed condition, and to 2 interventions - of which Matching Placebo is the first listed.
NCT01902303 reports a single indexed study location in Florida, Ohio, South Carolina.
Frequently Asked Questions
What is clinical trial NCT01902303 about?
NCT01902303 is a clinical study titled "Evaluation of Cold Sore Treatments on Ultra Violet (UV) Induced Cold Sores". The purpose of this study is to determine if a new drug treatment is effective to block the development of a cold sore lesion following Ultra Violet (UV) exposure.
What is the current status of trial NCT01902303?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 303 participants. The study started on 2013-07. Estimated completion is 2015-02.
What conditions does trial NCT01902303 study?
This clinical trial studies the following conditions: Oral Herpes Simplex.
What interventions are being tested in trial NCT01902303?
The interventions under investigation include: Matching Placebo (DRUG), BTL-TML-HSV (DRUG).
Who is sponsoring clinical trial NCT01902303?
This trial is sponsored by Beech Tree Labs, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01902303 being conducted?
This trial has 3 study locations across Florida, Ohio, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01902303's enrollment target sits among peer trials
303 167th of 2000 higher than 1,834 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05508971 · 303 participants · NA
Treatment of Obstructive Sleep Apnea With Personalized Surgery in Children With Down Syndrome (TOPS-DS)
- NCT04750616 · 304 participants · Phase 2
NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury Trial
- NCT04994717 · 304 participants · Phase 3
Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia
- NCT06036147 · 304 participants · NA
Concussion Health Improvement Program
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia